Similar articles

• Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.

  Scheen AJ, Gillet J, Rosenthaler J, Guiot J, Henrivaux P, Jandrain B, Lefèbvre PJ. Scheen AJ, et al. Diabetologia. 1989 Nov;32(11):801-9. doi: 10.1007/BF00264911. Diabetologia. 1989. PMID: 2687064
• A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.

  Krzentowski G, Scheen A, Castillo M, Luyckx AS, Lefèbvre PJ. Krzentowski G, et al. Diabetologia. 1983 May;24(5):314-8. doi: 10.1007/BF00251815. Diabetologia. 1983. PMID: 6347779 Clinical Trial.
• The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.

  Castillo MJ, Scheen AJ, Lefèbvre PJ. Castillo MJ, et al. J Clin Endocrinol Metab. 1996 May;81(5):1975-8. doi: 10.1210/jcem.81.5.8626867. J Clin Endocrinol Metab. 1996. PMID: 8626867
• Somatostatin and the endocrine pancreas.

  Gerich JE. Gerich JE. Curr Top Mol Endocrinol. 1976;3:127-43. doi: 10.1007/978-1-4684-2598-7_9. Curr Top Mol Endocrinol. 1976. PMID: 211005 Review.
• Somatostatin (growth hormone-release inhibiting hormone).

  Gomez-Pan A, Hall R. Gomez-Pan A, et al. Clin Endocrinol Metab. 1977 Mar;6(1):181-200. doi: 10.1016/s0300-595x(77)80063-7. Clin Endocrinol Metab. 1977. PMID: 196795 Review. No abstract available.